Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The 'Flip Off' star marked the holiday with a series of posts on social media Jen Juneau is a News and Movies Staff Writer at PEOPLE. She started at the brand in 2016 and has more than 15 years ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Toyota ...

Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...

We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands ...

H.C. Wainwright has recently reiterated Vertex Pharmaceuticals Inc (VRTX) stock to Buy rating, as announced on December 20, 2024, according to Finviz. Earlier, on December 19, 2024, Oppenheimer had ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $408.18, moving +0.72% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.1%.

Senores Pharmaceuticals IPO Allotment Today: At the upper price band, the company is valued at a P/E of 55x with a market cap of Rs 1800.6 crore (Image: Freepik) Senores Pharmaceuticals IPO closes ...